Purchase of LTQ-Orbitrap Hybrid Mass Spectrometer

描述(由申请人提供)：购买LTQ-Orbitrap混合质谱仪本提案旨在为购买超高性能Thermo Electron LTQ-Orbitrap混合质谱仪寻求资金。建议的仪器对UCI的许多NIH资助的研究项目至关重要，因为UCI校园内没有具有LTQ-Orbitrap MS功能的质谱仪。该仪器同时提供高灵敏度、分辨率、质量准确性、动态范围和吞吐量，这将增强我们对多肽和蛋白质进行测序的能力，以用于蛋白质鉴定和在attomole水平上对翻译后修饰的全面表征。其目标是使用基于质谱学的蛋白质组学方法来阐明包括癌症在内的各种人类疾病发展的分子机制。所要求的仪器将用于对26S蛋白酶体复合体(黄博士)、泛素化信号级联(Kaiser博士)、癌症中的调节蛋白(Lee博士)、逆转录病毒样核心颗粒(Sandmeyer博士)、Lef/Tcf-Catenin复合体(Watman博士)、免疫细胞离子通道信号(Cahalan博士)、亨廷顿病相关细胞因子(Marsh博士)、白念珠菌致病形式的二态转换和控制(刘博士)、作为潜在抗锥体药物靶点的RNA尿苷转移酶(Aphasizhev博士)、和癌症中线粒体完整性的调节(华莱士博士)新仪器的高性能将使人们有可能在常规基础上确定与疾病相关的蛋白质复合体的组成及其翻译后修饰。为了确保最大限度的使用和适当的维护，仪器将被安置在PI的质谱学实验室，黄博士。该研究所在蛋白质组学/生物质谱学领域拥有10多年的经验。卡哈兰博士将担任咨询委员会主席，负责对共享仪器的使用提供全面指导。伯林格姆博士将担任咨询委员会的外部成员。黄博士将与研究人员讨论实验策略，监督性能的优化，并确定调度的优先顺序。她的工作人员将对使用、培训和维护进行日常监督。UCI已同意提供15万美元用于购买拟议的仪器，并为仪器的维护和一名仪器运营商提供额外的财政支持，为期四年。这10名主要研究人员参与了美国国立卫生研究院资助的26个研究项目，他们对与人类健康和疾病相关的蛋白质组学研究的尖端技术的需求日益增长。所要求的仪器将是UCI医学院和生物科学学院生物医学研究的一个重要进步，作为五个不同系的成员共享的跨学科资源。

DESCRIPTION (provided by applicant): Purchase of the LTQ-Orbitrap hybrid mass spectrometer This proposal seeks funding for the purchase of an ultra high performance Thermo Electron LTQ-Orbitrap hybrid MS. The proposed instrument is essential to many NIH funded research programs at UCI as there is no mass spectrometer with the capabilities of the LTQ-Orbitrap MS available on the UCI campus. This instrument provides high sensitivity, resolution, mass accuracy, dynamic range and throughput simultaneously, which will enhance our ability to sequence peptides and proteins for protein identification and comprehensive characterization of posttranslational modifications at the attomole level. The goal is to use mass spectrometry-based proteomics approaches to elucidate the molecular mechanisms underlying the development of various human diseases including cancers. The requested instrument will be used to carry out detailed structure-function analyses of the 26S proteasome complex (Dr. Huang), ubiquitination signaling cascades (Dr. Kaiser), regulatory proteins in cancer (Dr. Lee), retro-virus-like core particles (Dr. Sandmeyer), LEF/TCF -catenin complexes (Dr. Waterman), immune cell ion channel signaling (Dr. Cahalan), cellular factors involved in Huntington disease (Dr. Marsh), dimorphic switching and control of pathogenic forms of C. albicans (Dr. Liu), RNA uridylyltransferases as potential anti-Trypanosome drug targets (Dr. Aphasizhev), and regulation of mitochondria integrity in cancer (Dr. Wallace). The high performance of the new instrumentation will make it possible to determine the composition of disease-related protein complexes and their posttranslational modifications on a routine basis. To ensure maximum usage and proper maintenance, the instrument will be housed in the mass spectrometry laboratory of the PI, Dr. Huang. The PI has over 10 years experience in the area of proteomics/biological mass spectrometry. Dr. Cahalan will chair the Advisory Committee responsible for overall guidance for the shared instrument's use. Dr. Burlingame will serve as an external Advisory Committee member. Dr. Huang will discuss experimental strategies with investigators, oversee optimization of performance and prioritize scheduling. Her staff member will provide daily supervision of usage, training and maintenance. UCI has agreed to provide $150k for the purchase of the proposed instrument, and additional financial support for the instrument's maintenance and an instrument operator for four years. The ten principal Investigators are involved in 26 NIH-supported research programs with growing needs for cutting-edge technology for their proteomics research related to human health and diseases. The requested instrument would represent an important advance for biomedical research in the UCI Schools of Medicine and Biological Sciences as a shared interdisciplinary resource for members of five different departments.